Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01398813 · ClinicalTrials.gov registry record
X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey
A clinical trial, sponsored by Edimer Pharmaceuticals.
- Completed
- Registry status
- 500
- Enrollment target
NCT01398813: Completed study, sponsored by Edimer Pharmaceuticals.
NCT01398813 is a clinical trial that has completed, run by Edimer Pharmaceuticals. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01398813 has completed, sponsored by Edimer Pharmaceuticals.
- COMPLETED
- Registry status
- 500 participants
- Enrollment target
Study Summary
In this survey of X-Lined Hypohidrotic Ectodermal Dysplasia (XLHED) carrier females, Edimer proposes to review responses to an XLHED Carrier Outlook toward Reproduction Survey in order to understand attitudes toward reproduction, potential treatments and genetic testing in order to improve the understanding of the decisions that XLHED carrier females make regarding their reproductive future.
Primary Outcome
Survey results will be collected during the 1 day of subject involvement.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-07 |
What the finished NCT01398813 record still lists
NCT01398813 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01398813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01398813 about?
NCT01398813 is a clinical study titled "X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey". In this survey of X-Lined Hypohidrotic Ectodermal Dysplasia (XLHED) carrier females, Edimer proposes to review responses to an XLHED Carrier Outlook toward Reproduction Survey in order to understand attitudes toward reproduction, potential treatments and genetic testing in order to improve the under...
What is the current status of trial NCT01398813?
This trial is currently completed. The enrollment target is 500 participants. The study started on 2011-07. Estimated completion is 2013-07.
Who is sponsoring clinical trial NCT01398813?
This trial is sponsored by Edimer Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia